Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2023 Sep 29;16:105. doi: 10.1186/s13045-023-01503-8

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Letong Cai 1,#, Yuchen Li 1,#, Jiaxiong Tan 1,#, Ling Xu 1,2,✉, Yangqiu Li 1,2,✉
PMCID: PMC10543833  PMID: 37773132

Correction to: Cai et al. Journal of Hematology & Oncology (2023) 16:101 10.1186/s13045-023-01499-1

The original article [1] contained an error mistakenly introduced by the production team whereby co-first authorship for the first three co-authors was omitted. This has since been restored accordingly.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Letong Cai, Yuchen Li and Jiaxiong Tan contributed equally to this work.

Contributor Information

Ling Xu, Email: lingxu114@163.com.

Yangqiu Li, Email: yangqiuli@hotmail.com.

Reference

  • 1.Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. doi: 10.1186/s13045-023-01499-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES